Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05896293
Other study ID # FD007843
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 3, 2023
Est. completion date June 30, 2027

Study information

Verified date April 2024
Source Massachusetts General Hospital
Contact Study Coordinator
Phone 617-724-8592
Email MGHKisspeptinResearch@partners.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Gonadotropin-releasing hormone (GnRH) may be administered subcutaneously (SC) for approximately six days in a pulsatile fashion, in order to prime the pituitary gland. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. Funding Source: FDA OOPD


Description:

Assignment: All study subjects will undergo the same interventions. Delivery of Interventions: - Each subject will undergo a review of their medical history, physical exam, and screening laboratories. - A pelvic ultrasound will be performed on women to assess baseline follicular size. - A pump may be placed to administer pulsatile SC GnRH for approximately six days. - A pump will be placed to administer pulsatile SC kisspeptin for two weeks. - During the course of kisspeptin administration, subjects will - Undergo q10 min blood sampling (approximately 10 sessions, 70 minutes each) - For women, undergo pelvic ultrasounds (approximately 3 sessions) - Optional q10 min sampling up to 8 hours may take place before and after the course of kisspeptin


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date June 30, 2027
Est. primary completion date June 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Congenital IHH o Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins - Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg) - Not using hormonal replacement or willing to complete an appropriate washout for that particular medication and method of administration - No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration Exclusion Criteria: - Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol - History of a medication reaction requiring emergency medical care - Excessive alcohol consumption (>10 drinks/week) and/or active use of illicit drugs o Any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation. Individuals who regularly use marijuana may be asked to washout as referenced in the medication washout section below. - Pregnant or trying to become pregnant - Breast feeding - History of bilateral oophorectomy (ovaries were removed)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
kisspeptin 112-121
SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
GnRH
SC administration of GnRH for approximately six days (pulsatile, every 120 minutes)

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Stephanie B. Seminara, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average change in luteinizing hormone (LH) pulse amplitude Average difference in LH amplitude after the first dose of kisspeptin (day 1) compared to the last dose of kisspeptin (day 15) 2 weeks
Secondary Percentage of female participants who demonstrate achievement of a mature follicle or show evidence of ovulation Percentage of female participants that develop a mature follicle or ovulate. Mature follicle achievement is defined as evidence of a follicle with maximum diameter =18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level. 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT01438073 - Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling Phase 1
Completed NCT01403532 - Sequential Therapy for Hypogonadotropic Hypogonadism Phase 4
Recruiting NCT00456274 - Baselines in Reproductive Disorders N/A
Terminated NCT05205837 - A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Phase 4
Completed NCT02908074 - A 6 Month Safety Extension Study of MBGS205 Phase 2
Completed NCT05752591 - Hypothalamic-pituitary Dysfunction in Diabetes
Terminated NCT03118479 - Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH) Phase 1
Completed NCT02730169 - Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism Phase 2
Completed NCT02110368 - Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions Phase 3
Recruiting NCT01601171 - Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
Completed NCT01623570 - Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP N/A
Terminated NCT00328926 - Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L]) Phase 4
Completed NCT01438034 - Kisspeptin in the Evaluation of Delayed Puberty Phase 1
Completed NCT04456296 - A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism Phase 4
Recruiting NCT00914823 - Kisspeptin Administration in the Adult Phase 1
Terminated NCT01155518 - Hypogonadism in Young Men With Type 2 Diabetes Phase 2
Completed NCT00697814 - Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Phase 2
Active, not recruiting NCT00351416 - Letrozole Treatment in Normal and GnRH Deficient Women Phase 2/Phase 3
Recruiting NCT05971836 - The Molecular Basis of Inherited Reproductive Disorders
Recruiting NCT02705014 - Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome N/A